AUS
NZ
UK
CA
USA
IND
Little Green Pharma Ltd has confirmed its Annual General Meeting (AGM) will take place virtually on August 13, 2026. The session will cover key resolutions including the election of directors and the re-approval of the company’s Long-Term Incentive Plan. Shareholders are encouraged to review the details and participate in the voting process.
Key Points
- Company and ASX ticker: Little Green Pharma Ltd (LGP)
- Primary update: Announcement of the Annual General Meeting with multiple resolutions on the agenda
- Important dates: AGM scheduled for August 13, 2026, at 9:30am (AWST) / 11:30am (AEST)
- Investor focus: Results of director elections and approval of the Long-Term Incentive Plan
Virtual AGM Set for August 13, 2026
Little Green Pharma Ltd will hold its Annual General Meeting virtually on Thursday, August 13, 2026, commencing at 9:30am (AWST) / 11:30am (AEST). The meeting will be hosted via a Zoom webinar, enabling shareholders to participate remotely. Registration and attendance instructions will be shared through the company’s announcements platform and official website.
Shareholders are urged to attend or submit proxy votes ahead of the meeting. The record date for voting eligibility is Tuesday, August 11, 2026, at 5:00pm (AWST) / 7:00pm (AEST). It is recommended that shareholders carefully review the Notice of Annual General Meeting and seek professional advice if necessary before casting their votes.
Agenda Highlights: Director Elections and Long-Term Incentive Plan
The AGM agenda features several critical resolutions, including the election of three directors: Mr Brent Dennison, Mr Thomas Huppert, and Mr Seth Yakatan. All were appointed on June 1, 2026, and are standing for election, subject to the terms outlined in the Explanatory Memorandum.
Additionally, the meeting will seek shareholder approval to re-approve the Little Green Pharma Ltd Long-Term Incentive Plan, which authorizes the issuance of up to 40,998,934 equity securities to incentivize employees. The agenda also includes approval of potential termination benefits under the plan, contingent on its re-approval. These resolutions are vital to the company’s governance and strategic objectives.
Resolution 1: Advisory Vote on Remuneration Report
The first resolution involves a non-binding advisory vote on the company’s Remuneration Report, which details the remuneration framework for key management personnel. Although advisory, this vote offers shareholders an opportunity to provide feedback on executive compensation practices.
Voting exclusions apply, preventing key management personnel and their closely related parties from voting on this resolution. Shareholders should review the Remuneration Report carefully to understand its impact on corporate governance and remuneration policies.
Director Elections: Brent Dennison, Thomas Huppert, and Seth Yakatan
Resolutions 2, 3, and 4 concern the election of directors Brent Dennison, Thomas Huppert, and Seth Yakatan. Each was appointed on June 1, 2026, and seeks election in accordance with the company’s constitution and the Explanatory Memorandum.
The election of these directors is crucial for determining the company’s leadership and strategic direction. Shareholders are encouraged to evaluate each candidate’s qualifications and contributions before voting.
Re-approval of Long-Term Incentive Plan
Resolution 5 requests shareholder re-approval of the Long-Term Incentive Plan, designed to align employee incentives with the company’s long-term objectives through equity securities issuance. Re-approval is essential for sustaining employee motivation and retention.
The plan’s terms and conditions are detailed in the Explanatory Memorandum. Shareholders will vote on this resolution, which plays a significant role in the company’s workforce engagement strategy.
Approval of Potential Termination Benefits
Resolution 6 seeks approval for potential termination benefits under the Long-Term Incentive Plan, conditional upon the plan’s re-approval. This resolution addresses benefits payable to managerial or executive personnel upon cessation of their office, in compliance with the Corporations Act.
Approving these benefits is important for regulatory compliance and competitive compensation. Shareholders should consider the governance and employee relations implications before voting.
Voting Exclusions and Restrictions
The company has specified voting exclusions for certain resolutions. For example, votes on Resolution 5 (Long-Term Incentive Plan) will be disregarded if cast by participants in the plan or their associates. Similarly, key management personnel and related parties are excluded from voting on Resolution 1 (Remuneration Report).
These measures ensure impartial voting outcomes. Shareholders should review the voting guidelines carefully to comply with all rules and avoid invalid votes.
Shareholder Engagement and Proxy Voting
Little Green Pharma Ltd stresses the importance of shareholder involvement in the AGM. Those unable to attend the virtual meeting are encouraged to submit proxy forms to ensure their votes count. Contact details for inquiries regarding the AGM or proxy process are provided by the company.
Participating in the AGM offers shareholders a chance to engage with company leadership and influence strategic decisions. The resolutions carry significant weight for governance, executive pay, and employee incentives.
Investor Guidance Post-AGM
Investors should monitor AGM outcomes closely, especially the director elections and Long-Term Incentive Plan approval, as these will impact the company’s leadership and strategic direction. No specific financial guidance or performance metrics were disclosed in the announcement.
The immediate effect on the share price remains unclear based on public information. Investors are advised to stay updated on any further announcements or developments following the AGM.
